SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation....
Hence then, the article about ind application for nts071 nutshell therapeutics p53 y220c allosteric reactivator received us fda clearance was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance )
Also on site :
- Hi3D V1.0 se vuelve de código abierto: el primer modelo 3D de IA de código abierto validado para producción
- ‘The Sopranos’ Star, 59, Opens up About His ‘Humiliating’ Medical Condition: ‘I Had to Start All Over Again’
- 100 Years Ago Today, Harry Houdini Took the Stage With a 104-Degree Fever, and It Was the Last Show He Ever Performed